Exagen Inc.
NASDAQ:XGNMedical - Diagnostics & Research
+$0.16 today
- Market cap
- $99.50M
- Beta
- 2.02
- P/E (TTM)
- -5.2
- EPS (TTM)
- -$0.85
Volume 0.47M
Average 0.39M
XGN Common Stock Issued
Cash raised by issuing new shares.
Exagen Inc.NASDAQ: XGN
Common Stock Issued · Q1 FY2026 · quarter ended Mar 2026
Common stock issued outflow grows to $295K
Q1 FY2026 common stock issued was $295K, compared with $0 a year earlier. Trailing-twelve-month common stock issued was $22.52M. Over 3 fiscal years it compounded at +269.1% a year.
Context
- Common stock issued amounted to 33.7% of revenue in FY2025, up 33.3 pp from a year earlier.
- Common stock issued increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly common stock issued holds near $295K or moves back toward the trailing-twelve-month quarterly average of $5.63M.
Sources:Cash FlowText generated from reported figures; not investment advice.
Common Stock Issued history
USD · from the cash flow
- Latest · FY2025
- 22.42M USD
- Year-over-year change
- +11224.7%
- 4-year CAGR
- -24.5%
| Period | Period end | Common Stock Issued | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 22.42M | +11224.7% |
| FY2024 | 2024-12-31 | 198K | -35.3% |
| FY2023 | 2023-12-31 | 306K | -31.4% |
| FY2022 | 2022-12-31 | 446K | -99.4% |
| FY2021 | 2021-12-31 | 69.14M | — |
Common Stock Issued vs competitors
How XGN compares with its peers on the latest reported figures
- XGN's LTM Mar 2026 common stock issued of $22.52M is the 3rd largest of the 11 companies compared; the peer median is $1.01M.
- Its year-over-year change of +23856.4% is the highest of 8, against a peer median of +90.0%.
- Common stock issued amounts to 32.9% of revenue for XGN, versus a peer median of 0.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
BIOABioAge Labs, Inc. | LTM Mar 2026 | $143.89M | +420.9% | +640.5% | 1394.8% |
| LTM Mar 2026 | $58.03M | -22.6% | — | 693.6% | |
| LTM Mar 2026 | $22.52M | +23856.4% | +269.1% | 32.9% | |
| LTM Mar 2026 | $19.45M | +6404.0% | +306.4% | 62.3% | |
| LTM Jun 2026 | $3.88M | +138.2% | -57.6% | 0.5% | |
| LTM Mar 2026 | $1.89M | +90.0% | +14.0% | 2.4% | |
| LTM Mar 2026 | $144K | -99.1% | -21.7% | 0.3% | |
| LTM Mar 2026 | $8K | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| LTM Mar 2026 | $0 | — | — | 0.0% | |
| FY2025 | $0 | -100.0% | — | 0.0% | |
| Peer median (excluding XGN) | $1.01M | +90.0% | +14.0% | 0.4% | |
Competitors are the stored peer set for XGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.85M) | (47.39M) | (23.69M) | (15.12M) | (19.95M) |
| Depreciation & Amortization | 948K | 1.56M | 2.17M | 1.72M | 2.12M |
| Deferred Income Tax | 148K | (306K) | 0 | 0 | 0 |
| Stock-Based Compensation | 4.73M | 4.7M | 3.62M | 1.76M | 2.16M |
| Change in Working Capital | (61K) | 1.67M | 325K | (3.08M) | (1.98M) |
| Accounts Receivables | (744K) | 3.58M | (474K) | (1.28M) | (3.02M) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (655K) | 901K | 67K | 308K | 42K |
| Other Working Capital | 1.34M | (2.81M) | 732K | (2.1M) | 997K |
| Other Non-Cash Items | 819K | 7.62M | 3.12M | 1.43M | 4.03M |
| Operating Cash Flow | (20.27M) | (32.14M) | (14.46M) | (13.28M) | (13.63M) |
| Capital Expenditures | (2.37M) | (4.32M) | (828K) | (515K) | (641K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 15K |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (50K) | 0 | 24K | 0 | 0 |
| Investing Cash Flow | (2.42M) | (4.32M) | (804K) | (515K) | (626K) |
| Debt Repayment | (525K) | (696K) | (10.94M) | (861K) | 2.01M |
| Common Stock Issued | 69.14M | 446K | 306K | 198K | 22.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (3.94M) | (239K) | 0 | 0 | 0 |
| Financing Cash Flow | 64.68M | (489K) | (10.63M) | (663K) | 24.44M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 41.99M | (36.95M) | (25.9M) | (14.46M) | 10.18M |
| Free Cash Flow | (22.64M) | (36.46M) | (15.29M) | (13.79M) | (14.27M) |
Exagen Inc.
NASDAQ:XGN
Intrinsic Alpha fair value
Locked
Current Price
$3.90
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.